Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.

In conclusion, thalidomide and gefitinib exhibit synergistic effects on both TKI-sensitive and -resistant NSCLC cells by targeting the EGFR signaling pathways, suggesting that the combination strategy is promising for the treatment of NSCLC.
PMID: 31132355 [PubMed - as supplied by publisher]

Source: European Journal of Pharmacology - May 23, 2019 Category: Drugs & Pharmacology Authors: Xia X, Liu Y, Liao Y, Guo Z, Huang C, Zhang F, Jiang L, Wang X, Liu J, Huang H Tags: Eur J Pharmacol Source Type: research